Helse Fonna HF
- Address
- Karmsundgata 120, 5528 Haugesund, Norway
Helse Fonna HF - Comprehensive Clinical Research Center
Helse Fonna HF is a multidisciplinary research center conducting innovative clinical trials across a diverse range of therapeutic areas. The center demonstrates particular strength in oncology research, with multiple trials investigating precision medicine approaches for lung cancer, breast cancer, and rare malignancies, as well as studies exploring targeted therapies based on genomic variants.
- Neurodegenerative disorders including Alzheimer's disease, dementia with Lewy bodies, multiple sclerosis, and mild cognitive impairment
- Advanced cancer therapies with focus on precision medicine, targeted treatments, and immunotherapy combinations for lung cancer, breast cancer, and rare malignancies
- Hematological conditions and endocrine disorders including immune thrombocytopenia and primary adrenal insufficiency
The center's research portfolio reflects a commitment to addressing unmet medical needs through personalized treatment approaches and comparative effectiveness trials. Notable studies include investigations of novel therapeutic combinations such as radiotherapy with immunotherapy in small-cell lung cancer, add-on therapies for multiple sclerosis, and second-line treatments for immune thrombocytopenia. The center's participation in precision oncology trials demonstrates expertise in genomic profiling and molecularly-targeted therapy selection for patients with advanced cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Oslo University Hospital HF2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Helse Bergen HF3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helse Fonna HF
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Dabrafenib, Trametinib, and Imatinib in the Treatment of Rare and Hard-to-Treat Cancers: A Clinical Trial on Drug Repurposing | Oslo University Hospital HF | Phase II | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dabrafenib | 2 | Unknown | 2021-04-01 | 2025-03-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.